Cargando…

Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia

Computed tomography (CT) scans used in treatment response assessment in prostate cancer (PCa) patients are a useful tool for nutritional status evaluation. The aim of this study was to assess the nutritional status, including sarcopenia development based on CT scans, in PCa patients and its associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Korczak, Jolanta, Mardas, Marcin, Litwiniuk, Maria, Bogdański, Paweł, Stelmach-Mardas, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096521/
https://www.ncbi.nlm.nih.gov/pubmed/37049485
http://dx.doi.org/10.3390/nu15071631
_version_ 1785024356599988224
author Korczak, Jolanta
Mardas, Marcin
Litwiniuk, Maria
Bogdański, Paweł
Stelmach-Mardas, Marta
author_facet Korczak, Jolanta
Mardas, Marcin
Litwiniuk, Maria
Bogdański, Paweł
Stelmach-Mardas, Marta
author_sort Korczak, Jolanta
collection PubMed
description Computed tomography (CT) scans used in treatment response assessment in prostate cancer (PCa) patients are a useful tool for nutritional status evaluation. The aim of this study was to assess the nutritional status, including sarcopenia development based on CT scans, in PCa patients and its association with progression-free survival (PFS). Sixty-four PCa patients were included (group 1: 34 patients undergoing androgen deprivation therapy (ADT) with docetaxel due to newly diagnosed, hormone-sensitive, metastatic PCa and group 2: 30 patients with castration-resistant metastatic PCa continuing ADT therapy with enzalutamide or abiraterone acetate). Nutritional status was evaluated with anthropometrical parameters, Nutritional Risk Score (NRS), and CT scans at the L3 vertebrae. Survival analyses were performed. According to NRS, nutritional status was significantly related to PFS. In both groups, there was a significant reduction in muscle tissue (total muscle tissue and skeletal muscle index). A significant increase in the distribution of adipose tissue (subcutaneous fat, visceral fat, subcutaneous adipose tissue index, and visceral adipose tissue index) in group one was observed. Sarcopenia was diagnosed in patients but with no influence on PFS. Significant reduction in muscle mass and increase in fat mass was observed in patients treated for PCa with no impact on PFS. The NRS was related to PFS in PCa patients and associated with body composition, assessed by CT after the castration therapy. Long-term castration combined with abiraterone therapy with prednisone or enzalutamide significantly influenced muscle tissue and may lead to sarcopenia development.
format Online
Article
Text
id pubmed-10096521
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100965212023-04-13 Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia Korczak, Jolanta Mardas, Marcin Litwiniuk, Maria Bogdański, Paweł Stelmach-Mardas, Marta Nutrients Article Computed tomography (CT) scans used in treatment response assessment in prostate cancer (PCa) patients are a useful tool for nutritional status evaluation. The aim of this study was to assess the nutritional status, including sarcopenia development based on CT scans, in PCa patients and its association with progression-free survival (PFS). Sixty-four PCa patients were included (group 1: 34 patients undergoing androgen deprivation therapy (ADT) with docetaxel due to newly diagnosed, hormone-sensitive, metastatic PCa and group 2: 30 patients with castration-resistant metastatic PCa continuing ADT therapy with enzalutamide or abiraterone acetate). Nutritional status was evaluated with anthropometrical parameters, Nutritional Risk Score (NRS), and CT scans at the L3 vertebrae. Survival analyses were performed. According to NRS, nutritional status was significantly related to PFS. In both groups, there was a significant reduction in muscle tissue (total muscle tissue and skeletal muscle index). A significant increase in the distribution of adipose tissue (subcutaneous fat, visceral fat, subcutaneous adipose tissue index, and visceral adipose tissue index) in group one was observed. Sarcopenia was diagnosed in patients but with no influence on PFS. Significant reduction in muscle mass and increase in fat mass was observed in patients treated for PCa with no impact on PFS. The NRS was related to PFS in PCa patients and associated with body composition, assessed by CT after the castration therapy. Long-term castration combined with abiraterone therapy with prednisone or enzalutamide significantly influenced muscle tissue and may lead to sarcopenia development. MDPI 2023-03-28 /pmc/articles/PMC10096521/ /pubmed/37049485 http://dx.doi.org/10.3390/nu15071631 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Korczak, Jolanta
Mardas, Marcin
Litwiniuk, Maria
Bogdański, Paweł
Stelmach-Mardas, Marta
Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title_full Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title_fullStr Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title_full_unstemmed Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title_short Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
title_sort androgen deprivation therapy for prostate cancer influences body composition increasing risk of sarcopenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096521/
https://www.ncbi.nlm.nih.gov/pubmed/37049485
http://dx.doi.org/10.3390/nu15071631
work_keys_str_mv AT korczakjolanta androgendeprivationtherapyforprostatecancerinfluencesbodycompositionincreasingriskofsarcopenia
AT mardasmarcin androgendeprivationtherapyforprostatecancerinfluencesbodycompositionincreasingriskofsarcopenia
AT litwiniukmaria androgendeprivationtherapyforprostatecancerinfluencesbodycompositionincreasingriskofsarcopenia
AT bogdanskipaweł androgendeprivationtherapyforprostatecancerinfluencesbodycompositionincreasingriskofsarcopenia
AT stelmachmardasmarta androgendeprivationtherapyforprostatecancerinfluencesbodycompositionincreasingriskofsarcopenia